Cardiovascular

Drug-eluting Stents: Cost-Benefit Targeting?

Matthias Pfisterer
Matthias Pfisterer

Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pfisterer from Basel. Audio Medica talked with him.

Click here for all the interviews from ESC 2005

Similar Interviews

  • Drug-eluting Stents: No Benefit in Vein Grafts
  • Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis

  • Patients with High Restenosis Risk Benefit More from Drug Eluting Stents
  • Raul Moreno REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria

  • Late-Stent Throbosis Risk after Clopidogrel Withdrawal: Greater in Drug Eluting Stents
  • Matthias Pfisterer, University Hospital Basel American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 422-11. Lancet 2005:366:921 Clopidogrel

    Post a comment

    Subscribe to Audio Medica Podcast